David Kandzari on Muck Rack

David Kandzari

Atlanta
As seen in: Wiley Online Library, The New England Journal of Medicine, The European Heart Journal, The Lancet, AHA/ASA Journals, Healio, Healio Cardiac/Vascular Intervention, Healio Cardiology, medRxiv, JACC: Cardiovascular Interventions and
Director, Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Two-Year Clinical Outcomes in Patients With Coronary Bifurcation Lesions: Results From the Onyx ONE Clear Study

|
By Christopher Garnett, David Kandzari, Matthew Price
| Journal of the Society for Cardiovascular Angiography & Interventions
Keywords bifurcation coronary artery disease drug-eluting stent short-term dual antiplatelet therapy zotarolimus-eluting stent Abbreviations DAPT (dual antiplatelet therapy) HBR (high bleeding risk) OAC (oral anticoagulation medication) PCI (percutaneous coronary intervention) RVD (reference vessel diameter) ST (stent thrombosis) TLR (target lesion revascularization) TVMI (target vessel myocardial infarction) TVR (target vessel revascularization) ZES (zotarolimus-eluting stent) Introduction...
Open in Who Shared Issue with article?

Long-term Clinical Benefit after Radiofrequency Renal Denervation: Pooled 36-Month Results from the SPYRAL Clinical Program

|
By David Kandzari, Michael Bohm, Kazuomi Kario
| PCR Online
Abstract Background: Catheter-based renal denervation (RDN) is a guideline-recommended therapy for uncontrolled hypertension. Late-term follow-up among RDN trials is essential to characterize the durability of efficacy, and further study is needed to ascertain the proportion of patients experiencing a clinical benefit.
Open in Who Shared Issue with article?

Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial

|
By David Kandzari
| AHA/ASA Journals
Research Article Open Access WHAT IS KNOWN • Results from the SPYRAL HTN-ON MED study demonstrated that renal denervation reduced office blood pressure compared with sham control at 6 months, and not 24-hour ambulatory blood pressure.
Open in Who Shared Issue with article?
See all 53 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified